Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Core Viewpoint - Mereo BioPharma Group plc is actively engaged in the development of innovative therapeutics for rare diseases and is participating in the Jefferies London Healthcare Conference to discuss its progress and future plans [1]. Company Overview - Mereo BioPharma is a clinical-stage biopharmaceutical company focused on rare diseases, with two main product candidates: setrusumab for osteogenesis imperfecta (OI) and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) [3]. - The partnership with Ultragenyx Pharmaceutical includes potential milestone payments of up to $245 million and royalties on commercial sales in Ultragenyx territories, while Mereo retains EU and UK commercial rights [3]. - Setrusumab has received orphan designation from both the EMA and FDA, along with several designations aimed at expediting its development [3]. - Alvelestat has also received U.S. Orphan Drug Designation and Fast Track designation from the FDA, with alignment on primary endpoints for a Phase 3 pivotal study [3]. - In addition to rare disease programs, Mereo is developing two oncology product candidates, etigilimab and navicixizumab, with ongoing clinical studies [3]. Upcoming Events - Dr. Denise Scots-Knight, CEO of Mereo BioPharma, will participate in a Fireside Chat at the Jefferies London Healthcare Conference on November 19, 2024, at 10:30 am ET / 03:30 pm GMT [1][2]. - A live audio webcast of the presentation will be available on the company's website, with an archived replay accessible for two weeks post-event [2].